文献速递炎症性肠病消化道肿瘤与早癌

肛周和/或会阴克罗恩病患者肛管癌和直肠癌风险高

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-12-02

基于法国CESAME观察性队列19486例炎症性肠病患者(14.9%有肛周和/或会阴克罗恩病),中位随访35个月,2911例肛周和/或会阴克罗恩病患者中发生2例肛管鳞状细胞癌、3例肛瘘相关腺癌和6例直肠癌,其发病率分别为0.26、0.38和0.77/1000患者年;肛周和/或会阴病变与肛管癌风险显著相关(OR 11.2)。

要点

  • 肛周和/或会阴克罗恩病患者肛管鳞状细胞癌发病率为0.26/1000患者年,肛瘘相关腺癌为0.38/1000患者年。
  • 肛周和/或会阴克罗恩病患者直肠癌发病率为0.77/1000患者年,无肛周病变者为0.21/1000患者年。
  • 肛周和/或会阴病变是肛管癌唯一显著相关因素(OR 11.2,95%CI 1.18-551.51,P=.03)。

核心结论

  • 肛周和/或会阴克罗恩病患者肛管癌(包括肛瘘相关癌)和直肠癌风险高。

研究设计与样本

  • 研究为法国CESAME观察性队列,纳入19486例炎症性肠病患者,2004年5月至2005年6月入组,14.9%有肛周和/或会阴克罗恩病,中位随访35个月(IQR 29-40)。

主要发现

  • 全体炎症性肠病人群中8例发生肛管癌,14例发生直肠癌。
  • 2911例肛周和/或会阴克罗恩病患者中,2例肛管鳞状细胞癌、3例肛瘘相关腺癌、6例直肠癌,发病率分别为0.26、0.38和0.77/1000患者年。
  • 16575例无肛周或会阴病变的溃疡性结肠炎或克罗恩病患者中,肛管癌发病率为0.08/1000患者年,直肠癌为0.21/1000患者年。
  • 单因素条件回归分析中,入组时存在肛周和/或会阴病变与肛管癌发生显著相关(OR 11.2,95%CI 1.18-551.51,P=.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about the magnitude of the risk of anal and rectal cancer in patients with anal and/or perineal Crohn's disease. We aimed to assess the risk of anal and rectal cancer in patients with Crohn's perianal disease followed up in the Cancers Et Surrisque Associé aux Maladies Inflammatoires Intestinales En France (CESAME) cohort. METHODS: We collected data from 19,486 patients with inflammatory bowel disease (IBD) enrolled in the observational CESAME study in France, from May 2004 through June 2005; 14.9% of participants had past or current anal and/or perianal Crohn's disease. Subjects were followed up for a median time of 35 months (interquartile range, 29-40 mo). To identify risk factors for anal cancer in the total CESAME population, we performed a case-control study in which participants were matched for age and sex. RESULTS: Among the total IBD population, 8 patients developed anal cancer and 14 patients developed rectal cancer. In the subgroup of 2911 patients with past or current anal and/or perianal Crohn's lesions at cohort entry, 2 developed anal squamous-cell carcinoma, 3 developed perianal fistula-related adenocarcinoma, and 6 developed rectal cancer. The corresponding incidence rates were 0.26 per 1000 patient-years for anal squamous-cell carcinoma, 0.38 per 1000 patient-years for perianal fistula-related adenocarcinoma, and 0.77 per 1000 patient-years for rectal cancer. Among the 16,575 patients with ulcerative colitis or Crohn's disease without anal or perianal lesions, the incidence rate of anal cancer was 0.08 per 1000 patient-years and of rectal cancer was 0.21 per 1000 patient-years. Among factors tested by univariate conditional regression (IBD subtype, disease duration, exposure to immune-suppressive therapy, presence of past or current anal and/or perianal lesions), the presence of past or current anal and/or perianal lesions at cohort entry was the only factor significantly associated with development of anal cancer (odds ratio, 11.2; 95% CI, 1.18-551.51; P = .03). CONCLUSIONS: In an analysis of data from the CESAME cohort in France, patients with anal and/or perianal Crohn's disease have a high risk of anal cancer, including perianal fistula-related cancer, and a high risk of rectal cancer.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Beaugerie L, Carrat F, Nahon S, et al. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clin Gastroenterol Hepatol. 2017. PMID: 29199142. doi:10.1016/j.cgh.2017.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。